Chapin Davis’s BlackRock Health Sciences Trust II BMEZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$406K Buy
26,454
+400
+2% +$5.75K 0.07% 166
2026
Q1
$374K Sell
26,054
-1,551
-6% -$23K 0.08% 181
2025
Q4
$415K Hold
27,605
0.1% 162
2025
Q3
$398K Buy
27,605
+849
+3% +$12.1K 0.1% 164
2025
Q2
$382K Buy
26,756
+6,400
+31% +$91.5K 0.11% 161
2025
Q1
$303K Buy
20,356
+500
+3% +$7.82K 0.1% 162
2024
Q4
$315K Hold
19,856
0.1% 166
2024
Q3
$315K Sell
19,856
-2,194
-10% -$34.6K 0.1% 167
2024
Q2
$339K Hold
22,050
0.12% 157
2024
Q1
$361K Buy
22,050
+5,500
+33% +$86.7K 0.13% 154
2023
Q4
$242K Hold
16,550
0.1% 180
2023
Q3
$238K Hold
16,550
0.11% 159
2023
Q2
$272K Hold
16,550
0.13% 156
2023
Q1
$277K Buy
16,550
+1,150
+7% +$18.5K 0.14% 158
2022
Q4
$238K Buy
+15,400
New +$238K 0.14% 158

Other funds holding BMEZ

Chapin Davis's BMEZ Position: Q2 2026 in Review

Chapin Davis increased its BlackRock Health Sciences Trust II (BMEZ) stake by 1.5% in Q2 2026, buying an estimated $5.75K and bringing the position to 26,454 shares worth $406K. The position accounts for 0.07% of the portfolio, ranked #166.

Chapin Davis first reported a position in BMEZ in Q4 2022 and has held it in 15 quarters since. The position peaked at $415K in Q4 2025. 88 funds tracked by Wall St. Rank hold BMEZ as of Q2 2026.

  • Chapin Davis held 26,454 shares of BlackRock Health Sciences Trust II worth $406K as of Q2 2026.
  • Chapin Davis bought 400 BlackRock Health Sciences Trust II shares in Q2 2026, an estimated $5.75K.
  • BlackRock Health Sciences Trust II made up 0.07% of Chapin Davis's portfolio in Q2 2026, its #166 holding.
  • Chapin Davis first reported a position in BlackRock Health Sciences Trust II in Q4 2022 and has held it in 15 quarters since.
  • Chapin Davis's BlackRock Health Sciences Trust II position peaked at $415K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held BlackRock Health Sciences Trust II as of Q2 2026.

Based on Chapin Davis's 13F filing for Q2 2026, filed 7 Jul 2026.